TesamorelinAlso known as: (3E)-hex-3-enoylsomatoliberin, N-(trans-3-hexenoyl)-[Tyr1]hGRF(1-44)NH2 acetate

Mechanism of Action

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) modified at the N- and C- termini to enhance stability and resistance to enzymatic degradation. It acts by binding to GHRH receptors on somatotrophs in the anterior pituitary gland, stimulating adenylate cyclase activity which converts ATP to cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA), leading to phosphorylation cascades that stimulate secretion of endogenous growth hormone (hGH). Elevated GH then promotes production of insulin-like growth factor-1 (IGF-1) primarily from hepatocytes and locally in tissues, modulating anabolic, lipolytic, and growth-promoting effects. Tesamorelin increases overall GH secretion (AUC increase ~69%) and IGF-1 levels (~122%) without significantly affecting GH pulse frequency or peak.

Reported Research Benefits

Primarily researched for reduction of visceral adipose tissue and treatment of lipodystrophy, especially in HIV-associated fat redistribution disorders. Potential effects include improving lipid profiles, reducing hepatic fat fraction, possible cognitive benefits in mild cognitive impairment related to immunodeficiency, and muscle tissue quality enhancements. It is also investigated for metabolic regulation and insulin sensitivity modulation, though no significant changes in glucose control have been observed.

Dosing Protocol & Reconstitution

Common research dosing includes administration of Tesamorelin in daily injections, typically over periods of 12 to 26 weeks or longer depending on study protocols. Typical reported doses in clinical settings are 2 mg/day subcutaneously for lipodystrophy treatment. The vendor offers it as 5mg and 10mg lyophilized powder quantities intended for research use, with dosing protocols adjusted accordingly by researchers.

Research Notes

Phase III clinical trials in subjects with HIV-associated lipodystrophy showed a significant reduction (~15.4%) in visceral adipose tissue after 26 weeks of Tesamorelin treatment alongside improved lipid parameters. A 12-month study demonstrated reduction in hepatic fat fraction (HFF) in 35% of patients vs 4% placebo in HIV-positive subjects with NAFLD. Cognitive effects in immunodeficient patients with mild cognitive impairment are under investigation in ongoing studies. A 12-week trial in type II diabetics showed no significant effect on insulin sensitivity or glycemic control. Imaging studies indicate potential increases in muscle tissue density and volume in select muscle groups. Tesamorelin’s half-life in circulation is approximately 26 to 30 minutes, but its effects on GH and IGF-1 levels persist longer due to downstream signaling.

Research Summary

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue that has been extensively studied in clinical trials for its ability to reduce visceral adipose tissue in HIV-infected patients with lipodystrophy. It has demonstrated efficacy in increasing endogenous growth hormone secretion, thereby improving body composition, lipid profiles, and potentially reducing cardiovascular risk factors. The strongest evidence arises from randomized controlled trials showing significant reductions in visceral fat over 26 weeks of treatment, although long-term safety and efficacy data remain limited. Limitations include its specificity to HIV-associated lipodystrophy populations and the need for further studies to confirm benefits in other groups.

Side Effects & Safety

Known side effects of tesamorelin primarily include injection site reactions, joint pain, muscle aches, and peripheral edema, as observed in human clinical trials. Due to its mechanism of stimulating growth hormone release, there is potential for increased glucose intolerance or insulin resistance, and monitoring is recommended in diabetic or prediabetic individuals. Animal studies have not revealed significant toxicities, but theoretical risks include stimulation of tumor growth due to elevated GH/IGF-1 axis activity. Drug interactions have not been extensively reported, but caution is advised when used alongside other agents affecting glucose metabolism or pituitary function. Tesamorelin is not currently listed as a prohibited substance by the World Anti-Doping Agency (WADA).

Stability & Storage

Refer to research notes

Molecular Data

Sequence: N-(trans-3-hexenoyl)-[Tyr1]-hGRF(1-44)-NH2 acetate
Molecular Formula: C221H366N72O67S
Molecular Weight: 5136 g/mol

Primary literature: https://pubmed.ncbi.nlm.nih.gov/?term=tesamorelin